Elan moves to deter takeover bid

by Shawn Pogatchnik

(AP)—Irish drug maker Elan Corp. announced Monday it will pay shareholders a recurring special dividend linked to the sales of the multiple sclerosis treatment Tysabri.

Analysts said the offer, contingent on Elan's pending sale of its Tysabri rights to partner Biogen Idec Inc., was designed to deter shareholders from considering a by Royal Pharma.

Elan said it planned to pay shareholders 20 percent of its Tysabri received from Biogen twice annually beginning in the fourth quarter this year.

"This dividend structure gives shareholders the right to enjoy unlimited participation in the upside from the Tysabri sales increase which we anticipate for the future," Elan said in a statement.

Elan and Biogen jointly developed Tysabri and have split earnings since the drug's troubled in the U.S. market in 2004. They soon withdrew Tysabri from sale after three MS sufferers using the drug contracted PML, a rare brain-inflammation disease that is often fatal.

But since its return to sale in 2006 under restricted conditions Tysabri has gradually gained market traction because, despite its PML risks, it is considered most effective at reducing the frequency and severity of sudden or partial paralysis experienced by . The neurological disease MS has no cure.

Last month Elan agreed to sell its interest in Tysabri to Biogen, based in Weston, Massachusetts, for $3.25 billion in cash and recurring .

Royal Pharma launched a $6.5 billion bid for Elan on Feb. 25 that values the Dublin-based company at approximately $11 a share. Royal Pharma argued that Elan's shareholders should sell because the company already was too heavily reliant on Tysabri sales, but Elan's directors rejected the bid as cynically timed to exploit uncertainty among some Elan shareholders.

Elan's shares have risen 27 percent since the Tysabri sale plans were announced Feb. 6. They rose a further 1 percent on Monday to €8.71 ($11.33) on the Irish Stock Exchange.

The royalty agreement means Biogen will pay Elan 12 percent of its revenue from Tysabri sales this year and 18 percent in future years. Should Tysabri sales break the $2 billion annual barrier, as is expected, Elan will receive 25 percent of the proceeds from sales over that threshold. Tysabri's sales totaled $1.6 billion in 2012.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

FDA clears safety test to screen Tysabri patients

Jan 20, 2012

(AP) -- The Food and Drug Administration on Friday approved a new diagnostic test to help identify patients who have an increased risk of developing a rare brain infection while taking Biogen Idec's multiple sclerosis drug ...

Leukoencephalopathy risk factors ID'd for MS drug

May 17, 2012

(HealthDay) -- Drug company researchers say they've determined which multiple sclerosis patients are most vulnerable to developing a rare brain infection while taking a powerful drug called Tysabri (natalizumab).

Taiwan design house files complaint against Apple

Mar 30, 2010

A Taiwanese company said Tuesday it had filed a complaint against Apple urging the US to prevent the electronics giant from selling touchscreen products such as the iPhone, iPod and the new iPad.

Recommended for you

New MCAT shifts focus, will include humanities

Oct 20, 2014

(HealthDay)—The Medical College Admission Test (MCAT) has been revised, and the latest changes, including more humanities such as social sciences, are due to be implemented next April, according to a report ...

User comments